
trans-8-Chloro-5-ethyl-1-[4-(5-fluoro-pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene,
trans-8-Chloro-5-ethyl-1-[4-(6-methyl-pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene, and
trans-8-Chloro-5-methyl-1-[4-(6-methyl-pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene.

24. A selective V1a antagonist for the treatment and/or prevention of phase shift sleep disorders, wherein the V1a antagonist is



example 1.

25. A V1a antagonist for the preparation of medicaments for the treatment and/or prevention of phase shift sleep disorders.

26. A V1a antagonist according to any one of claims 5-13 for the preparation of medicaments for the treatment and/or prevention of phase shift sleep disorders.

27. The use of a V1a antagonist for the preparation of medicaments for the treatment and/or prevention of phase shift sleep disorders.

28. The use of a V1a antagonist according to any one of claims 5-13 for the preparation of medicaments for the treatment and/or prevention of phase shift sleep disorders.

~~29. The invention as described hereinabove.~~